BR112018003127A2 - purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes - Google Patents

purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes

Info

Publication number
BR112018003127A2
BR112018003127A2 BR112018003127A BR112018003127A BR112018003127A2 BR 112018003127 A2 BR112018003127 A2 BR 112018003127A2 BR 112018003127 A BR112018003127 A BR 112018003127A BR 112018003127 A BR112018003127 A BR 112018003127A BR 112018003127 A2 BR112018003127 A2 BR 112018003127A2
Authority
BR
Brazil
Prior art keywords
fkpa
methods
bacteria
purification
multispecific antibodies
Prior art date
Application number
BR112018003127A
Other languages
English (en)
Inventor
Ladiwala Asif
B Fong Chris
A Mckay Patrick
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR112018003127A2 publication Critical patent/BR112018003127A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/99—Isomerases (5.)

Abstract

a presente invenção proporciona métodos para a produção de polipeptídeo de peptidil-prolil cis-trans isomerase (fkpa) tipo fkbp com níveis muito elevados de pureza. também são fornecidos fkpa ultrapuros e métodos de uso dos mesmos, por exemplo, para uso em imunoensaios para mostrar a remoção de fkpa de produtos biológicos produzidos em bactérias. além disso, a presente invenção proporciona métodos para purificar polipeptídeos (por exemplo, anticorpos multiespecíficos) produzidos em bactérias que sobre-expressam uma ou mais chaperonas. os métodos incluem cromatografia de afinidade, cromatografia em modo misto e cromatografia de interação hidrofóbica. em alguns aspectos, a invenção proporciona composições de polipeptídeo (por exemplo, anticorpos multiespecíficos) que são essencialmente isentos de impurezas específicas do produto.
BR112018003127A 2015-08-20 2016-08-19 purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes BR112018003127A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562207908P 2015-08-20 2015-08-20
US201562207910P 2015-08-20 2015-08-20
US201562210378P 2015-08-26 2015-08-26
PCT/US2016/047912 WO2017031476A2 (en) 2015-08-20 2016-08-19 Purification of fkpa and uses thereof for producing recombinant polypeptides

Publications (1)

Publication Number Publication Date
BR112018003127A2 true BR112018003127A2 (pt) 2018-09-25

Family

ID=58052052

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018003127A BR112018003127A2 (pt) 2015-08-20 2016-08-19 purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes

Country Status (13)

Country Link
US (1) US20180327446A1 (pt)
EP (1) EP3337819B1 (pt)
JP (2) JP7091238B2 (pt)
KR (1) KR20180048731A (pt)
CN (1) CN108473558A (pt)
AU (1) AU2016308383A1 (pt)
BR (1) BR112018003127A2 (pt)
CA (1) CA2995385A1 (pt)
HK (1) HK1259368A1 (pt)
IL (2) IL257400A (pt)
MX (1) MX2018002068A (pt)
TW (1) TW201718623A (pt)
WO (1) WO2017031476A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
AU2018385759B2 (en) 2017-12-14 2021-10-21 Flodesign Sonics, Inc. Acoustic transducer driver and controller
WO2019129877A1 (en) * 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Process for providing pegylated protein composition
JP7449041B2 (ja) * 2018-02-27 2024-03-13 ファイザー・インク 抗体精製
AU2019240135A1 (en) * 2018-03-21 2020-10-22 Takeda Pharmaceutical Company Limited Separation of VWF and VWF propeptide by chromatographic methods
WO2019193418A1 (en) 2018-04-05 2019-10-10 Bio-Rad Abd Serotec Gmbh Display systems for proteins of interest
KR20210075101A (ko) * 2018-09-25 2021-06-22 아이크노스 사이언스 에스. 아. 생물학적 샘플에서의 항체 정량법
CN114409798A (zh) * 2019-02-14 2022-04-29 美勒斯公司 制备包含两种或更多种抗体的组合物
EP3942079A1 (en) 2019-03-18 2022-01-26 Bio-Rad ABD Serotec GmbH Protection of spytag-containing periplasmic fusion proteins from protease tsp and ompt degradation
CA3137116A1 (en) * 2019-05-03 2020-11-12 Genentech, Inc. Methods of reducing the enzymatic hydrolysis activity rate in a composition obtained from a purification platform
KR20220122678A (ko) * 2019-12-20 2022-09-02 머크 샤프 앤드 돔 엘엘씨 엔테로바이러스의 정제된 조성물 및 글루타티온 친화성 크로마토그래피를 이용한 정제 방법
US20230357315A1 (en) * 2020-03-11 2023-11-09 Dr. Reddy's Laboratories Limited METHOD OF PURIFYING AN Fc-FUSION PROTEIN

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002061090A2 (en) * 2000-12-14 2002-08-08 Genentech, Inc. Prokaryotically produced antibodies and uses thereof
KR20110025649A (ko) * 2008-05-05 2011-03-10 노비뮨 에스 에이 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
CA2932207A1 (en) 2008-10-20 2010-12-09 Abbvie Inc. Isolation and purification of antibodies using protein a affinity chromatography
RS60577B1 (sr) 2009-10-20 2020-08-31 Abbvie Inc Izolacija i prečišćavanje anti-il-13 antitela upotrebom protein a afinitetne hromatografije
WO2013028330A2 (en) 2011-08-19 2013-02-28 Emd Millipore Corporation Methods of reducing level of one of more impurities in a sample during protein purification
KR101498771B1 (ko) 2011-12-15 2015-03-09 한화케미칼 주식회사 항체의 정제 방법
TW201333035A (zh) * 2011-12-30 2013-08-16 Abbvie Inc 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
BR112015015948B1 (pt) 2013-01-09 2022-05-17 Takeda Pharmaceutical Company Limited Método de purificação da proteína arilsulfatase a (asa) recombinante
WO2014165771A2 (en) * 2013-04-05 2014-10-09 Genentech, Inc. Anti-il-4 antibodies and bispecific antibodies and uses thereof
SG11201508642WA (en) * 2013-04-19 2015-11-27 Sutro Biopharma Inc Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones
EP3036253B1 (en) * 2013-08-19 2020-09-23 F. Hoffmann-La Roche AG Separation of bispecific antibodies and bispecific antibody production side products using hydroxyapatite chromatography
NZ756749A (en) * 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
WO2015070068A1 (en) 2013-11-07 2015-05-14 Abbvie Inc. Isolation and purification of antibodies
BR112016018980A2 (pt) * 2014-02-21 2017-10-10 Genentech Inc método de tratamento de um distúrbio, anticorpo multiespecífico, ácido nucleico isolado, célula hospedeira, métodos de produzir um anticorpo, de produção de uma metade de anticorpo ou de um anticorpo multiespecífico e de produção de um anticorpo multiespecífico, imunoconjugado e formulação farmacêutica

Also Published As

Publication number Publication date
HK1259368A1 (zh) 2019-11-29
MX2018002068A (es) 2018-06-06
IL257400A (en) 2018-04-30
US20180327446A1 (en) 2018-11-15
TW201718623A (zh) 2017-06-01
KR20180048731A (ko) 2018-05-10
AU2016308383A1 (en) 2018-03-15
EP3337819A2 (en) 2018-06-27
CA2995385A1 (en) 2017-02-23
JP2022062046A (ja) 2022-04-19
JP7091238B2 (ja) 2022-06-27
IL288205A (en) 2022-01-01
WO2017031476A2 (en) 2017-02-23
JP2018533355A (ja) 2018-11-15
EP3337819B1 (en) 2024-02-21
EP3337819C0 (en) 2024-02-21
WO2017031476A3 (en) 2017-04-13
CN108473558A (zh) 2018-08-31

Similar Documents

Publication Publication Date Title
BR112018003127A2 (pt) purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
BR112018004965A2 (pt) domínios de superfamìlia de imunoglobulina variante ajustàvel
BR112018070934A2 (pt) proteínas imunomoduladoras variantes ligantes de icos e usos das mesmas
WO2017024317A3 (en) Methods to induce targeted protein degradation through bifunctional molecules
BR112018075516A2 (pt) purificação de anticorpos multiespecíficos
BR112015019879A2 (pt) Composições de espécies de variantes moduladas de lisina e métodos para produção e uso das mesmas
BR112016002614A8 (pt) Imunocitoquina, ácido nucleico, vetor, célula hospedeira e composição farmacêutica
BR112016029318A2 (pt) tratamento de mielomas
PE20170665A1 (es) Anticuerpos anti-tau humanizados
CL2015002655A1 (es) Moduladores de p2x7
MX2021010668A (es) Proteinas de fusion de citoquinas.
BR112016003196A8 (pt) método para separar anticorpos biespecíficos
BR112017010069A2 (pt) redução seletiva de resíduos cisteína em anticorpos para il-17
SG10201902850TA (en) Human-derived anti-dipeptide repeats (dprs) antibody
EA201690958A1 (ru) Депрессанты для применения в способах разделения
CL2018002769A1 (es) Composiciones y métodos recombinantes de inmunoglobulina intravenosa (rlvig) para producción y uso.
BR112017001417A2 (pt) variantes de proteína de ligação ao fator h e métodos para uso das mesmas
MX2022011973A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
EA201691834A1 (ru) Новый способ очистки гонадотропина
BR112022008092A2 (pt) Métodos de preparação de uma amostra enriquecida para sequenciamento polipeptídico
TW201613981A (en) Compositions and methods for the diagnosis of rheumatoid arthritis

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2736 DE 13-06-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.